News
Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China ...
Grand Pharmaceutical Group Limited (0512.HK, "Grand Pharma" or the "Group") announces that the Phase II clinical study for the treatment of sepsis in China of the global innovative drug STC3141, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback